# PT-141 Research Summary: Mechanism, Trials & Brain Imaging > PT-141 (bremelanotide) research: central MC4R mechanism, the RECONNECT Phase 3 trials, fMRI evidence in women, the male erectile-dysfunction data, and the open debates — cited. From the rat and primate pharmacology to the imaged human brain — what each study established, and where its standing ends. ## Before the details The PT-141 research record divides cleanly into three layers. First, the basic pharmacology: PT-141 (bremelanotide) switches on brain receptors called MC3R and MC4R, and animal work showed this changes sexual behavior through the brain rather than through blood vessels [1][2]. Second, the human female evidence: two large trials and a year-long follow-up in premenopausal women with HSDD, plus a brain-scan study that watched the mechanism work [3][4][5]. Third, the older male erectile-dysfunction line, which produced real signals but never an approval for men [1]. Keeping those layers straight is the whole point. A finding in rats is a finding in rats. A signal in men with erectile dysfunction is exactly that — a research signal, not an approved use [1]. The approval lives only in the female-HSDD layer [7]. Each section below states what was measured and in whom. ## The central mechanism PT-141 acts on the brain. It is an agonist at the melanocortin receptors MC3R and MC4R, which are expressed primarily in the central nervous system — concentrated in the hypothalamus and limbic system [1]. By stimulating MC4R in hypothalamic circuits such as the medial preoptic area (a region central to sexual motivation), it is thought to engage dopamine pathways that drive sexual desire [1]. The foundational pharmacology paper showed that systemic administration produced penile erections in rats and nonhuman primates and activated hypothalamic neurons, and produced rapid, dose-dependent erectile activity in men with erectile dysfunction [1]. The contrast with the familiar erectile-dysfunction pills is mechanistic and complete: those act peripherally on vascular smooth muscle, while PT-141 acts on the neural circuitry of sexual motivation itself [1]. ## PT-141 peptide: the preclinical female work The PT-141 peptide earned its female-sexual-function reputation in animal models first. In female rats, the peptide selectively stimulated appetitive, solicitational sexual behaviors — the proceptive, desire-driven kind — without affecting lordosis, pacing, or general motor activity [2]. That selectivity mattered: it was the first reported pharmacological agent acting specifically on appetitive female sexual behavior, and it pointed to central melanocortin systems as regulators of female desire [2]. Not every preclinical result was confirmatory, and the digest reports the nuance. In female Syrian hamsters, MC3R/MC4R messenger RNA was concentrated in dopamine neurons of the ventral tegmental area, but bremelanotide did not change melanocortin-receptor expression in that mesolimbic system and did not enhance sexual reward in a place-preference test — suggesting it may not act on the classic VTA–nucleus-accumbens reward circuit [6]. That is a careful negative finding, and it sits in the record alongside the positive ones. ## The human female evidence The strongest human data is in women, and it is substantial. Two identical Phase 3 trials (RECONNECT, 1,267 premenopausal women with HSDD) showed bremelanotide 1.75 mg subcutaneous as-needed met both coprimary endpoints — desire up by an integrated +0.35 and desire-distress down by −0.33, each P<.001 over 24 weeks [3]. A 52-week open-label extension in 684 women sustained those gains with no new safety signals [4]. The mechanism was then imaged. In a placebo-controlled crossover fMRI study of 31 women with HSDD, MC4R agonism increased sexual desire for up to 24 hours and altered task-based brain processing of erotic stimuli, enhancing amygdala–insula connectivity [5]. A 2026 systematic review and meta-analysis confirmed improvements in total Female Sexual Function Index scores and the desire and arousal subscales across pooled trials [12], while a 2026 ClinicalTrials.gov analysis named bremelanotide among the most-studied HSDD pharmacotherapies but flagged heterogeneity and inconsistent safety reporting across studies [13]. ## PT-141 for men The male erectile-dysfunction line is part of the history and is read as off-label research throughout this digest. PT-141 was first developed as a nasal spray for erectile dysfunction and female sexual dysfunction, with a completed Phase IIb erectile-dysfunction trial and Phase III trials planned at the time [9]. The foundational pharmacology likewise documented rapid, dose-dependent erectile activity in men with erectile dysfunction [1]. But that program did not lead to an approval for men, and the intranasal route was later set aside for pharmacokinetic variability in favor of subcutaneous dosing [9]. One older male-ED salvage study (Safarinejad & Hosseini, 2008) received a 2023 Expression of Concern and should be treated as disputed [appears in references]. The takeaway: male use of PT-141 is off-label and investigational, not approved — the data is real, the approval is not [7]. ## The debates worth carrying A complete research summary keeps the criticism in view. Independent re-analyses argue the trial effects on desire and distress, while significant, are small, and question their clinical meaningfulness and the outcome measures used; one notes bremelanotide produced no additional enjoyable sexual experiences on average and argues the approval leaned on regulatory precedent [11]. Reviews of HSDD itself flag a lack of diagnostic consensus and a debate about the medicalization of low desire [8]. There are also off-label populations with no efficacy data: a clinician guide to managing HSDD in transgender women lists bremelanotide among centrally acting options while explicitly noting efficacy evidence in that group is lacking [14]. The pattern across the literature is consistent — a genuine, approved, central-mechanism drug for one narrow group, surrounded by uses where the evidence thins or runs out. --- A regulatory-careful reading room on PT-141 (bremelanotide): the single 2019 approval for premenopausal HSDD held distinct from every off-label and research-chemical use, each figure logged to the trials or the FDA label — a reading desk organized around the prescription record, never a place that writes, fills, or fulfils one.